Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App





Oncolab Exhibits Pioneering AMAS Cancer Test at AACC

By LabMedica International staff writers
Posted on 29 Jul 2014
The Oncolab (Boston, MA, USA) laboratory-developed AMAS cancer test is making its AACC debut at this year's 2014 conference. More...
To date, the test, which is a serum-based in vitro immunoassay, has been run for over 60,000 patients and appears to be an emerging tool in the fight against cancer recurrence as well as detection.

There are an estimated 17 million cancer survivors in the US alone, hence there is a race to develop better technologies for identifying whether a cancer has begun to recur, and if so at what rate. There is a clear trend towards the use of immunoassays in cancer diagnostics, as immunotherapy for treatment. The AMAS test fits into these trends by measuring the level of a specific antibody, Anti-Malignin Antibody, which is thought to be produced by the body's immune system in response to nearly all forms of cancer.

Most other cancer immunoassays measure circulating cancer antigens, which become elevated later than the antibody measured in the AMAS test. Therefore, the AMAS Test helps to pick up recurrence at an early stage when levels of anti-malignin antibody are often elevated early in the occurrence and recurrence of cancer. This is a distinctive capability—false positive and false negative rates are under 10%. While the AMAS test does provide guidance to the likely location of the cancer, new high-resolution imaging techniques, more location-specific cancer tests, and clinical signs help the clinician provide patients with a fuller picture of the disease.

Currently, Oncolab provides the test via submission of samples to its CLIA-certified laboratory in Boston. Serum samples must be shipped via overnight courier, using a standardized shipping container and tubes provided at no cost by Oncolab, dry ice obtained at the lab while doing the blood draw, and separation to serum. The test is approved by the US Food and Drug Administration (FDA) and reimbursed by Medicare.

Today, the majority of samples being run are drawn in the US and Canada; overseas labs can also ship samples and are urged to contact Oncolab to get a technical and business relationship started.

The AMAS test, by Oncolab, is a pioneering cancer diagnostic test measuring levels of a circulating antibody which is elevated in nearly all types of cancer. The test has been run for over 60,000 patients at Oncolab's CLIA-certified facility in Boston. The test is able to detect early cases of cancer recurrence, a major concern for 17 million Americans. This year is the company's debut at the AACC (American Association for Clinical Chemistry), being held in Chicago - booth #4051.

Related Links:

Oncolab



Gold Member
Quality Control Material
iPLEX Pro Exome QC Panel
Portable Electronic Pipette
Mini 96
Gold Member
Cardiovascular Risk Test
Metabolic Syndrome Array I & II
Alcohol Testing Device
Dräger Alcotest 7000
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: The new method can contribute to earlier detection of cirrhosis and liver cancer (Photo courtesy of 123RF)

Simple Test Predicts Risk of Severe Liver Disease

Severe liver diseases such as cirrhosis and liver cancer are becoming increasingly common and often carry a poor prognosis when detected late. Current screening tools are limited in their ability to identify... Read more

Hematology

view channel
Image: New evidence shows viscoelastic testing can improve assessment of blood clotting during postpartum hemorrhage (Photo courtesy of 123RF)

Viscoelastic Testing Could Improve Treatment of Maternal Hemorrhage

Postpartum hemorrhage, severe bleeding after childbirth, remains one of the leading causes of maternal mortality worldwide, yet many of these deaths are preventable. Standard care can be hindered by delays... Read more

Immunology

view channel
Image: Automated cell imaging discriminates CD8+ T cells according to natalizumab treatment outcome in MS patients (B Chaves et al., Nat Commun 16, 5533 (2025). DOI: 10.1038/s41467-025-60224-3)

Novel Tool Predicts Most Effective Multiple Sclerosis Medication for Patients

Multiple sclerosis (MS) is a chronic autoimmune and degenerative neurological disease that affects the central nervous system, leading to motor, cognitive, and mental impairments. Symptoms can include... Read more

Technology

view channel
Image: The SWITCH hybrid pipette is designed to simplify and accelerate pipetting tasks (Photo courtesy of INTEGRA)

Hybrid Pipette Combines Manual Control with Fast Electronic Aliquoting

Manual pipettes offer the control needed for delicate tasks such as mixing or supernatant removal, but typically fall short in repetitive workflows like aliquoting. Electronic pipettes solve this problem... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.